September 14, 2020
Daiichi Sankyo said on September 11 that it has filed an application in Japan, seeking an additional usage and dosage for its anticoagulant edoxaban for elderly patients with non-valvular atrial fibrillation and high bleeding risk. The filing is based on...read more